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ABSTRACT 
The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) was established in 2004 to monitor longitudinal changes in bacterial susceptibility to 
numerous antimicrobial agents, specifically tigecycline. In this study, susceptibility among Gram-positive and Gram-negative isolates between 
2004 and 2011 from the Middle East and Africa was examined. Antimicrobial susceptibilities were determined using Clinical and Laboratory 
Standards Institute (CLSI) interpretive criteria, and minimum inhibitory concentrations (MICs) were determined by broth microdilution methods. 
US Food and Drug Administration (FDA)-approved breakpoints were used for tigecycline. In total, 2967 Gram-positive and 6322 Gram-negative 
isolates were examined from 33 participating centres. All Staphylococcus aureus isolates, including meticillin-resistant S. aureus, were 
susceptible to tigecycline, linezolid and vancomycin. Vancomycin, linezolid, tigecycline and levofloxacin were highly active (>97.6% susceptibility) 
against Streptococcus pneumoniae, including penicillin-non-susceptible strains. All Enterococcus faecium isolates were susceptible to tigecycline 
and linezolid, including 32 vancomycin-resistant isolates. Extended-spectrum β-lactamases were produced by 16.6% of Escherichia coli and 
32.9% of Klebsiella pneumoniae. More than 95% of E. coli and Enterobacter spp. were susceptible to amikacin, tigecycline, imipenem and 
meropenem. The most active agents against Pseudomonas aeruginosa and Acinetobacter baumannii were amikacin (88.0% susceptible) and 
minocycline (64.2% susceptible), respectively; the MIC90 (MIC required to inhibit 90% of the isolates) of tigecycline against A. baumannii was low 
at 2 mg/L. Tigecycline and carbapenem agents were highly active against most Gram-negative pathogens. Tigecycline, linezolid and vancomycin 
showed good activity against most Gram-positive pathogens from the Middle East and Africa. 
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1. Introduction 
Antimicrobial resistance has been reported to all major groups of antibiotics and is a cause of global concern. Resistance has appeared in the 
Middle East and Africa over the past decade (e.g. carbapenem-resistant Acinetobacter baumannii in Lebanon [1] and extended-spectrum β-
lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae in South Africa [2]). Antimicrobial surveillance is critical for monitoring 
emerging trends in antimicrobial resistance and for guiding clinicians to appropriate empirical antimicrobial therapy. 
 
Tigecycline, a broad-spectrum antimicrobial agent, is licensed for the treatment of complicated skin and intra-abdominal infections (as well as 
community-acquired bacterial pneumonia in the USA) [3]. The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a global surveillance 
study designed to monitor bacterial susceptibility to tigecycline and comparator antimicrobial agents. We report on the activity of tigecycline and 
comparators against Gram-positive and Gram-negative pathogens from the Middle East and Africa between 2004 and 2011. This paper updates 
some of the data presented by Bertrand and Dowzicky [4], who examined antimicrobial susceptibility among Gram-negative isolates from North 
America, Europe, the Asia-Pacific Rim, Latin America, the Middle East and Africa collected as part of T.E.S.T. between 2004 and 2009. 
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2. Materials and methods 
2.1. Isolate collection 
Isolates were collected from 33 centres in the Middle East and Africa between 2004 and 2011 (Israel, 10 centres, 2005–2011; Jordan, 1 centre, 
2009–2011; Lebanon, 1 centre, 2006–2007; Mauritius, 1 centre, 2009; Namibia, 1 centre, 2008–2009; Oman, 1 centre, 2006–2007; Pakistan, 3 
centres, 2004–2006; Saudi Arabia, 3 centres, 2009 and 2011; and South Africa, 12 centres, 2004–2009 and 2011). 
 
Each centre was expected to contribute at least 65 Gram-positive and 135 Gram-negative isolates annually, including 15 Streptococcus 
pneumoniae, 15 Enterococcus spp., 25 Staphylococcus aureus, 10 Streptococcus agalactiae, 15 Haemophilus influenzae, 15 Acinetobacter 
spp., 25 E. coli, 25 Enterobacter spp., 20 Pseudomonas aeruginosa, 10 Serratia spp. and 25 Klebsiella spp. isolates. All isolates were to be 
collected consecutively and considered clinically significant as determined by local criteria. They could be of nosocomial or community origin. 
Only one isolate was permitted per patient; isolate inclusion was independent of patient age, sex, previous medical history and/or previous 
antimicrobial use. 
 
2.2. Susceptibility testing 
Minimum inhibitory concentrations (MICs) were determined locally based on broth microdilution methodology as described by the Clinical and 
Laboratory Standards Institute (CLSI) [5] using Sensititre® plates (TREK Diagnostic Systems, East Grinstead, UK) or MicroScan® panels 
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(Siemens, Sacramento, CA). The test panel for Gram-positive pathogens included amoxicillin/clavulanic acid (AMC), ampicillin, ceftriaxone, 
imipenem (MicroScan® only), levofloxacin, linezolid, meropenem (Sensititre® only), minocycline, penicillin, piperacillin/tazobactam (TZP), 
tigecycline and vancomycin. Gram-negative isolates were tested against amikacin, AMC, ampicillin, cefepime, ceftazidime, ceftriaxone, 
imipenem, levofloxacin, meropenem, minocycline, TZP and tigecycline. As a result of stability issues, imipenem was replaced by meropenem in 
2006; MicroScan® panels were replaced by Sensititre® plates that same year. MIC determinations were carried out using cation-adjusted 
Mueller–Hinton broth (Streptococcus spp. were cultured in Mueller–Hinton broth supplemented with lysed horse blood). In 2008, the test panel 
for S. pneumoniae was extended to include azithromycin, clarithromycin, clindamycin and erythromycin; this means that some isolates were 
tested retrospectively. 
 
Laboratories International for Microbiology Studies, a division of International Health Management Associates, Inc. (IHMA, Schaumburg, IL), was 
responsible for isolate collection and transport as well as the management of a centralised T.E.S.T. database; IHMA’s role in T.E.S.T. has been 
described in detail elsewhere [6]. 
 
Antimicrobial susceptibility was determined using interpretive criteria as described by the CLSI [7]; non-meningeal oral breakpoints have been 
applied to S. pneumoniae. US Food and Drug Administration (FDA)-approved breakpoints were used for tigecycline, as provided in the 
tigecycline package insert [3]. Statistically significant changes in susceptibility were identified using the Cochran–Armitage test for trend. 
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2.3. Extended-spectrum β-lactamase testing 
ESBL production was examined among E. coli and Klebsiella spp. according to CLSI guidelines [6,7]. 
 
3. Results 
In total, 2967 Gram-positive and 6322 Gram-negative isolates were collected in the Middle East and Africa between 2004 and 2011 (Tables 1 
and 2). Isolates were submitted from 33 centres in nine countries; most isolates originated from Israel (52.9%) or South Africa (28.4%). 
 
3.1. Gram-positive isolates 
All 1216 isolates of S. aureus were susceptible to linezolid, tigecycline and vancomycin; susceptibility to minocycline was also high at 96.4% 
(Table 1a). Overall, 27.8% of S. aureus isolates were meticillin-resistant S. aureus (MRSA), with a rate of almost 50% noted from Mauritius 
(Table 3). MRSA prevalence was low in Namibia, Pakistan and Oman, ranging from 12.5% to 13.8%; in the remaining countries, the MRSA 
incidence ranged from 23.8% to 45.8%. Only 18.6% of MRSA isolates were susceptible to levofloxacin (Table 1a); among all meticillin-
susceptible S. aureus isolates, levofloxacin susceptibility decreased significantly (P < 0.05) from 100% in 2004 to 94.9% in 2010 before 
increasing to 98.0% in 2011 (only 51 isolates were available in 2011; data not shown). 
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Streptococcus pneumoniae (n = 598) were highly susceptible (≥97.6%) to vancomycin, linezolid, tigecycline and levofloxacin, including penicillin-
non-susceptible isolates (Table 1a). Macrolide susceptibility was lowest in Jordan (Table 1b), which also showed the highest rates of penicillin-
non-susceptible S. pneumoniae (Table 3). Streptococcus agalactiae (n = 465) were highly susceptible to vancomycin, penicillin, meropenem, 
linezolid, ceftriaxone and ampicillin (each 100%), levofloxacin (98.5%) and tigecycline (94.2%). However, only 16.1% of isolates were susceptible 
to minocycline (Table 1a). 
 
Among Enterococcus faecalis (n = 565), ≥99.5% susceptibility was observed for ampicillin, linezolid, penicillin, tigecycline and vancomycin (Table 
1a); levofloxacin and minocycline susceptibilities were 56.3% and 26.9%, respectively. A single vancomycin-resistant E. faecalis isolate was 
collected in Israel. Susceptibility rates were lower among Enterococcus faecium (n = 123) than E. faecalis, although 100% susceptibility was 
reported for linezolid and tigecycline (Table 1a). Twenty-six percent of E. faecium isolates were vancomycin-resistant (Tables 1a and 3). 
 
3.2. Gram-negative isolates 
Enterobacter spp. (n = 1137) showed high (≥95%) susceptibility to amikacin, imipenem, meropenem and tigecycline; <5% of isolates were 
susceptible to AMC or ampicillin (Table 2a). 
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Escherichia coli (n = 1238) were highly susceptible (≥96.5%) to tigecycline, amika in, imipenem and meropenem (Table 2a); a single tigecycline-
non-susceptible isolate was collected from Jordan. ESBL production was noted among 16.6% of E. coli (Table 3) but had little effect on the 
activity of tigecycline, amikacin and the carbapenems (Tables 2a). Levofloxacin susceptibility ranged from 33.3% in Jordan to 91.3% in Namibia. 
Low susceptibility rates were noted in Jordan (Table 2a), likely due to higher numbers of ESBL-producing coliforms there (62.5%) (Table 3). 
ESBL production in E. coli was lowest in Lebanon (0.0%), South Africa (3.7%) and Namibia (4.3%) (Table 3). 
 
Klebsiella pneumoniae (n = 1105) were highly susceptible to imipenem (96.6%), tigecycline (93.4%) and amikacin (91.0%). Levofloxacin 
susceptibility ranged from 56.3% in Israel to 100% in Namibia and Oman (Table 2a). ESBLs were produced by 32.9% of isolates (Table 3) but 
did not impact the activity of imipenem or amikacin; tigecycline susceptibility decreased to 88.7% (Table 2a). ESBL production was lowest in 
Oman (4.2%) and Namibia (13.0%) (Table 3). Among Klebsiella oxytoca isolates (n = 121), ≥93.7% were susceptible to amikacin, tigecycline and 
meropenem (Table 2a). 
 
Among Serratia marcescens isolates (n = 444), high susceptibility (≥94.1%) was observed for meropenem, amikacin, cefepime, TZP, imipenem, 
tigecycline and levofloxacin (Table 2a); S. marcescens is intrinsically resistant to AMC and ampicillin. 
 
Amikacin was highly active against P. aeruginosa (n = 975; 88.0% susceptible); low susceptibility to several antimicrobials was observed in 
Pakistan (Table 2). The most active agent against A. baumannii (n = 664) was minocycline (64.2% susceptible) (Table 2a). A low tigecycline 
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MIC90 (MIC required to inhibit 90% of the isolates) (2 mg/L) was recorded for A. baumannii. Overall susceptibility was low in Pakistan (Table 2). 
Among non-A. baumannii Acinetobacter spp. (n = 33), 84.8% and 66.7% of isolates were susceptible to minocycline and meropenem, 
respectively; an MIC90 of 1 mg/L for tigecycline to non-A. baumannii was observed. 
 
Haemophilus influenzae (n = 605) were highly susceptible (≥97.9%) to most agents on the T.E.S.T. panel (Table 2a). β-Lactamase-positive H. 
influenzae were rare in most countries (<10 in Jordan, Lebanon, Mauritius, Oman, Pakistan and Saudi Arabia). 
 
3.3. Changes in susceptibility 
Significant (P < 0.01) changes in susceptibility were examined only in Israel and South Africa owing to insufficient isolate numbers from other 
countries. In Israel, significant decreases in minocycline susceptibility were noted among A. baumannii (95.8% in 2006 to 55.0% in 2010; P < 
0.0001), Enterobacter spp. (82.6% in 2006 to 59.4% in 2010; P < 0.001) and S. pneumoniae (92.6% in 2006 to 47.7% in 2010; P < 0.0001). A 
significant decrease in tigecycline susceptibility was noted among S. marcescens (100% in 2006 to 82.4% in 2010; P < 0.01). A significant 
increase in meropenem susceptibility occurred among E. coli: 77.6% of isolates were susceptible in 2007 (n = 98), increasing to 100% in 2009 (n 
= 207) and 2010 (n = 176) (P < 0.0001) [100% susceptibility was also recorded in 2005 and 2006, but isolate numbers were considerably lower 
(n = 9 and 39, respectively)]. In South Africa, a significant decrease in susceptibility was noted among A. baumannii to TZP (52.9% in 2005 to 
27.1% in 2006; P < 0.01), although isolate numbers were low (≤6) between 2007 and 2011 (data not shown). 
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4. Discussion 
Staphylococcus aureus and enterococci susceptibility rates resemble reports from other recent studies. Staphylococcus aureus susceptibility to 
tigecycline, linezolid and vancomycin was 100% in the current study. These results corroborate findings in a recent report from Lebanon [8], 
although vancomycin-resistant S. aureus isolates have been reported in the region [9]. Salem-Bekhit et al. [10] reported 3.9% vancomycin 
resistance among 206 clinical isolates of enterococci collected in Saudi Arabia between 2009 and 2012. These results resemble those given 
here, as 33 (4.8%) vancomycin-resistant enterococci (32 E. faecium and 1 E. faecalis) were seen from the Middle East and Africa in the current 
study; 16 enterococci were collected from Saudi Arabia, of which 1 single isolate (6.3%) was vancomycin-resistant. 
 
T.E.S.T. intensive care unit (ICU) isolates from the Middle East and Africa between 2004 and 2009 have previously been described [4]. 
Acinetobacter baumannii isolates were 7–17% less susceptible to cefepime, ceftazidime, meropenem and TZP compared with the 2004–2011 
interval, likely due in part to the 2004–2009 data containing only ICU isolates, which are generally more resistant than non-ICU isolates. These 
changes may also be due to changes in participating centres that occur in surveillance studies. 
 
Although not indicated for the treatment of infections caused by Acinetobacter spp., tigecycline is often regarded as a viable treatment option for 
multidrug-resistant Acinetobacter infections [11]. The Enterobacteriaceae susceptibility breakpoint (≤2 mg/L) is often used for tigecycline in the 
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absence of CLSI tigecycline susceptibility breakpoints. An MIC90 of 2 mg/L was re orded for tigecycline against Acinetobacter in the current 
study. Low tigecycline resistance in Lebanon (0% resistant, 2% intermediate) and Kuwait (13.6% resistant) reflected good activity against 
Acinetobacter reported in the current study [8,12]. 
 
Previous studies have reported 100% tigecycline susceptibility among E. coli isolates from Lebanon and Oman, including ESBL-producers 
[12,13]. Only one single (0.1%) non-susceptible E. coli isolate from Jordan was reported in the current study. No E. coli ESBL production was 
observed from Lebanon, possibly due to sampling error: in comparison, another recent study demonstrated ESBL production among E. coli of 
30% in a tertiary care centre in Lebanon in 2011 [8]. Two imipenem-non-susceptible isolates of K. pneumoniae were collected in the current 
study, one of which was resistant to tigecycline. Meropenem resistance occurred among 103 isolates (77 from Israel, 22 from South Africa, 2 
from Saudi Arabia and 1 each from Pakistan and Mauritius); of these, 2 (1.9%) were also resistant to tigecycline (data not shown). Araj et al. [8] 
also reported good results for tigecycline among ESBL-positive K. pneumoniae isolates collected in Lebanon, with only 3% tigecycline-resistant 
and 16% intermediate. 
 
Sader et al. have recently published susceptibility results for tigecycline against more than 22 000 clinical bacteria collected worldwide as a part 
of the SENTRY study in 2011 [14]; the tigecycline results presented here for the Middle East and Africa broadly agree with these global results. 
Staphylococcus aureus, Enterococcus spp., S. pneumoniae and E. coli from the Middle East/Africa were each within 1% of global results (all 
above 99% susceptible), whilst Acinetobacter shared an MIC90 of 2 mg/L in both studies. Enterobacter and Klebsiella susceptibility to tigecycline 
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were slightly lower in Middle East/Africa than globally. Enterobacter spp. susceptibility was 95.5% in Middle East/Africa compared with 98.6% 
globally, whilst K. pneumoniae and K. oxytoca were 93.4% and 96.7% susceptible, respectively, in the current study, whilst 98.6% of Klebsiella 
spp. were susceptible to tigecycline worldwide. 
 
Tigecycline resistance mechanisms have recently been summarised by Linkevicius et al. [15]. Resistance–nodulation–division (RND) efflux 
pumps are used by several bacteria [Acinetobacter spp., Enterobacter cloacae, E. coli, K. pneumoniae, Morganella spp. (AcrAB), Proteus spp. 
(AcrAB), Providencia spp., P. aeruginosa (MexXY–OprM) and Salmonella enterica] to reduce susceptibility to tigecycline. Efflux pumps are also 
responsible for tigecycline resistance among Burkholderia spp., whilst overexpression of multidrug and toxin extrusion (MATE) family efflux 
pumps (MepA) may reduce tigecycline susceptibility among S. aureus isolates. Although still uncommon, resistance to those agents commonly 
used against multidrug-resistant pathogens, such as tigecycline and colistin, has occurred in some regions [11]. Molecular resistance 
mechanisms are not identified as part of T.E.S.T. 
 
Tigecycline retains in vitro activity against a wide range of organisms collected from the Middle East and Africa. The results presented highlight 
the importance of newer antimicrobial agents such as tigecycline, which do not share cross-resistance with other commonly used antibacterial 
drugs [3]. The question of whether the in vitro activity of tigecycline corresponds to clinical efficacy is unclear. Tigecycline may offer an addition to 
the limited armamentarium available for the management of infections caused by increasingly resistant pathogens. 
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Table 1a 
MIC90 values (in mg/L) and percent antimicrobial susceptibility (%S) among Gram-positive isolates (including resistant phenotypes) collected in 
the Middle East and Africa between 2004 and 2011 a,b 
AMC AMP CRO IPM LVX LZD MEM MIN PEN TZP TIG  N 
MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S 
Staphylococcus aureus 
Israel 631 ≥16 71.8 ≥32 11.3 ≥128 70.8 – – 16 68.8 4 100 ≥32 
(n = 
631) 
76.7 0.5 98.1 ≥16 9.8 ≥32 74.3 0.5 100 
Jordan 29 8 69.0 ≥32 3.4 ≥128 65.5 – – 4 89.7 4 100 8 (n 
= 29) 
89.7 0.5 96.6 ≥16 3.4 ≥32 82.8 0.25 100 
Lebanon 25 8 88.0 ≥32 8.0 64 84.0 0.25 
(n = 
25) 
96.0 0.25 92.0 2 100 – – ≤0.25 100 ≥16 8.0 8 96.0 0.25 100 
Mauritius 24 ≥16 58.3 ≥32 12.5 ≥128 54.2 – – 8 66.7 4 100 ≥32 
(n = 
24) 
66.7 8 62.5 ≥16 12.5 ≥32 62.5 0.25 100 
Namibia 24 8 87.5 ≥32 8.3 16 87.5 – – 0.5 91.7 2 100 4 (n 
= 24) 
91.7 ≤0.25 100 ≥16 8.3 8 91.7 0.25 100 
Oman 29 4 93.1 ≥32 10.3 16 89.7 – – 0.5 100 2 100 0.5 (n 
= 29) 
100 ≤0.25 100 ≥16 10.3 4 100 0.12 100 
Pakistan 62 8 88.7 ≥32 8.1 64 85.5 1 (n 
= 46) 
93.5 8 83.9 4 100 ≥32 
(n = 
16) 
81.3 1 95.2 ≥16 6.5 16 88.7 0.5 100 
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Saudi 
Arabia 
42 ≥16 76.2 ≥32 4.8 ≥128 76.2 – – 8 78.6 2 100 ≥32 
(n = 
42) 
78.6 ≤0.25 95.2 ≥16 4.8 ≥32 78.6 0.25 100 
South 
Africa 
350 ≥16 77.7 ≥32 7.1 ≥128 76.3 ≥32 
(n = 
106) 
74.5 8 79.1 2 100 ≥32 
(n = 
244) 
84.0 4 95.1 ≥16 6.6 ≥32 78.9 0.25 100 
All 
countries 
1216 ≥16 75.3 ≥32 9.4 ≥128 73.9 ≥32 
(n = 
177) 
82.5 16 75.0 4 100 ≥32 
(n = 
1039)
79.7 1 96.4 ≥16 8.4 ≥32 77.9 0.25 100 
Meticillin-resistant S. aureus 
Israel 190 ≥16 6.3 ≥32 0.0 ≥128 6.8 – – ≥64 8.4 4 100 ≥32 
(n = 
190) 
22.6 0.5 96.3 ≥16 0.0 ≥32 14.7 0.25 100 
Jordan 9 – [0] – [0] – [0] – – – [7] – [9] – (n 
= 9) 
[6] – [8] – [0] – [4] – [9] 
Lebanon 8 – [5] – [0] – [4] – [7] – [6] – [8] – – – [8] – [0] – [7] – [8] 
Mauritius 11 ≥16 9.1 ≥32 0.0 ≥128 0.0 – – 8 27.3 4 100 ≥32 
(n = 
11) 
27.3 ≥16 27.3 ≥16 0.0 ≥32 18.2 0.5 100 
Namibia 3 – [0] – [0] – [0] – – – [1] – [3] – (n 
= 3) 
[1] – [3] – [0] – [1] – [3] 
Oman 4 – [2] – [0] – [1] – – – [4] – [4] – (n 
= 4) 
[4] – [4] – [0] – [4] – [4] 
Pakistan 8 – [1] – [0] – [0] – [2] – [0] – [8] – (n 
= 3) 
[0] – [5] – [0] – [1] – [8] 
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Saudi 
Arabia 
10 ≥16 0.0 ≥32 0.0 ≥128 0.0 – – 16 10.0 2 100 ≥32 
(n = 
10) 
10 8 80.0 ≥16 0.0 ≥32 10.0 0.25 100 
South 
Africa 
95 ≥16 17.9 ≥32 0.0 ≥128 16.8 ≥32 
(n = 
44) 
38.6 8 26.3 2 100 ≥32 
(n = 
51) 
23.5 8 84.2 ≥16 0.0 ≥32 22.1 0.5 100 
All 
countries 
338 ≥16 11.2 ≥32 0.0 ≥128 10.1 ≥32 
(n = 
57) 
45.6 32 18.6 2 100 ≥32 
(n = 
281) 
24.9 8 89.3 ≥16 0.0 ≥32 20.4 0.5 100 
Streptococcus pneumoniae 
Israel 336 2 92.0 4 NA 1 92.3 – – 1 97.3 1 100 1 (n 
= 
336) 
75.9 ≥16 59.2 2 51.8 4 NA 0.03 99.7
Jordan 14 4 50.0 8 NA 2 78.6 – – 2 100 1 100 1 (n 
= 14) 
21.4 ≥16 28.6 4 7.1 8 NA 0.03 100 
Mauritius 9 – [7] – NA – [7] – – – [9] – [9] – (n 
= 9) 
[4] – [0] – [2] – NA – [9] 
Oman 15 1 100 2 NA 1 100 – – 1 100 1 100 0.5 (n 
= 15) 
73.3 2 93.3 2 53.3 2 NA 0.03 100 
Pakistan 32 0.12 100 0.25 NA 0.25 100 0.25 
(n = 
15) 
86.7 1 93.8 1 100 ≤0.12 
(n = 
17) 
100 8 50.0 0.25 62.5 ≤0.25 NA 0.06 100 
Saudi 
Arabia 
18 2 94.4 4 NA 2 83.3 – – 1 100 1 100 0.5 (n 
= 18) 
55.6 ≥16 44.4 4 22.2 4 NA 0.06 94.4
South 
Africa 
174 4 85.6 4 NA 1 97.1 0.5 (n 
= 50) 
52.0 1 100 1 99.4 1 (n 
= 
124) 
63.7 4 82.8 2 31.6 4 NA 0.03 98.3
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All 
countries 
598 4 89.6 4 NA 1 93.5 0.5 (n 
= 65) 
60.0 1 98.2 1 99.8 1 (n 
= 
533) 
71.1 8 64.4 2 44.1 4 NA 0.03 99.2
Penicillin-non-susceptible S. pneumoniae c 
Israel 162 4 83.3 4 NA 2 84.0 – – 2 95.1 1 100 1 (n 
= 
162) 
50.0 ≥16 52.5 4 0.0 4 NA 0.03 100 
Jordan 13 4 46.2 8 NA 2 76.9 – – 2 100 1 100 1 (n 
= 13) 
15.4 ≥16 30.8 4 0.0 8 NA 0.03 100 
Mauritius 7 – [5] – NA – [5] – – – [7] – [7] – (n 
= 7) 
[2] – [0] – [0] – NA – [7] 
Oman 7 – [7] – NA – [7] – – – [7] – [7] – (n 
= 7) 
[3] – [6] – [0] – NA – [7] 
Pakistan 12 0.25 100 0.5 NA 0.25 100 – (n 
= 5) 
[3] 0.5 100 1 100 – (n 
= 7) 
[7] ≥16 33.3 0.5 0.0 0.5 NA 0.06 100 
Saudi 
Arabia 
14 2 92.9 4 NA 2 78.6 – – 1 100 1 100 0.5 (n 
= 14) 
42.9 ≥16 35.7 4 0.0 4 NA 0.03 92.9
South 
Africa 
119 4 79.0 4 NA 1 95.8 0.5 (n 
= 36) 
33.3 1 100 1 99.2 1 (n 
= 83) 
45.8 8 77.3 4 0.0 4 NA 0.06 98.3
All 
countries 
334 4 81.4 4 NA 2 88.3 0.5 (n 
= 41) 
36.6 1 97.6 1 99.7 1 (n 
= 
293) 
47.4 ≥16 58.7 4 0.0 4 NA 0.03 99.1
Streptococcus agalactiae 
Israel 255 0.12 NA 0.12 100 0.12 100 – – 1 97.3 1 100 ≤0.12 
(n = 
255) 
100 ≥16 20.0 0.12 100 0.5 NA 0.12 100 
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Jordan 15 0.12 NA 0.12 100 0.25 100 – – 1 100 2 100 0.5 (n 
= 15) 
100 ≥16 26.7 0.12 100 0.5 NA 0.5 66.7
Lebanon 10 0.12 NA 0.12 100 0.12 100 ≤0.12 
(n = 
10) 
NA 1 100 1 100 – – ≥16 30.0 0.12 100 ≥32 NA 2 0 
Mauritius 9 – NA – [9] – [9] – – – [9] – [9] – (n 
= 9) 
[9] – [0] – [9] – NA – [9] 
Namibia 5 – NA – [5] – [5] – – – [5] – [5] – (n 
= 5) 
[5] – [0] – [5] – NA – [5] 
Oman 8 – NA – [8] – [8] – – – [8] – [8] – (n 
= 8) 
[8] – [1] – [8] – NA – [8] 
Pakistan 24 0.12 NA 0.12 100 0.12 100 0.25 
(n = 
15) 
NA 1 100 1 100 – (n 
= 9) 
[9] ≥16 8.3 0.12 100 ≤0.25 NA 0.06 100 
Saudi 
Arabia 
16 0.12 NA 0.12 100 0.12 100 – – 1 100 1 100 ≤0.12 
(n = 
16) 
100 ≥16 18.8 ≤0.06 100 ≤0.25 NA 0.5 68.8
South 
Africa 
123 0.12 NA 0.12 100 0.12 100 0.5 (n 
= 41) 
NA 1 100 1 100 ≤0.12 
(n = 
82) 
100 ≥16 8.9 0.12 100 ≤0.25 NA 0.12 94.3
All 
countries 
465 0.12 NA 0.12 100 0.12 100 0.25 
(n = 
66) 
NA 1 98.5 1 100 ≤0.12 
(n = 
399) 
100 ≥16 16.1 0.12 100 0.5 NA 0.12 94.2
Enterococcus faecalis 
Israel 284 1 NA 2 99.6 ≥128 NA – – ≥64 52.8 2 100 8 (n 
= 
284) 
NA ≥16 27.1 4 99.6 8 NA 0.25 99.6
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Jordan 28 1 NA 2 100 ≥128 NA – – ≥64 53.6 2 100 8 (n 
= 28) 
NA ≥16 28.6 4 100 8 NA 0.25 100 
Mauritius 9 – NA – [9] – NA – – – [1] – [9] – (n 
= 9) 
NA – [1] – [9] – NA – [9] 
Namibia 13 1 NA 1 100 ≥128 NA – – 32 76.9 2 100 8 (n 
= 13) 
NA ≥16 38.5 4 100 8 NA 0.25 100 
Oman 15 0.5 NA 1 100 ≥128 NA – – 32 66.7 2 100 4 (n 
= 15) 
NA 8 40.0 2 100 4 NA 0.12 100 
Pakistan 23 2 NA 2 100 ≥128 NA 2 (n 
= 11) 
NA ≥64 43.5 2 100 ≥32 
(n = 
12) 
NA 8 17.4 8 100 16 NA 0.12 100 
Saudi 
Arabia 
8 – NA – [8] – NA – – – [4] – [8] – (n 
= 8) 
NA – [2] – [8] – NA – [8] 
South 
Africa 
185 1 NA 1 100 ≥128 NA 4 (n 
= 54) 
NA ≥64 63.8 2 99.5 8 (n 
= 
131) 
NA ≥16 26.5 4 100 4 NA 0.12 100 
All 
countries 
565 1 NA 2 99.8 ≥128 NA 4 (n 
= 65) 
NA ≥64 56.3 2 99.8 8 (n 
= 
500) 
NA ≥16 26.9 4 99.8 8 NA 0.25 99.8
Enterococcus faecium 
Israel 79 ≥16 NA ≥32 22.8 ≥128 NA – – ≥64 16.5 2 100 ≥32 
(n = 
79) 
NA ≥16 51.9 ≥16 26.6 ≥32 NA 0.25 100 
Jordan 5 – NA – [2] – NA – – – [1] – [5] – (n 
= 5) 
NA – [4] – [1] – NA – [5] 
Mauritius 3 – NA – [1] – NA – – – [1]  [3] – (n 
= 3) 
NA – [3] – [1] – NA – [3] 
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Oman 1 – NA – [0] – NA – – – [0]  [1] – (n 
= 1) 
NA – [1] – [0] – NA – [1] 
Pakistan 13 ≥16 NA ≥32 7.7 ≥128 NA – (n 
= 9) 
NA ≥64 15.4 2 100 – (n 
= 4) 
NA ≥16 38.5 ≥16 7.7 ≥32 NA 0.12 100 
Saudi 
Arabia 
8 – NA – [2] – NA – – – [1] – [8] – (n 
= 8) 
NA – [5] – [0] – NA – [8] 
South 
Africa 
14 ≥16 NA ≥32 28.6 ≥128 NA – (n 
= 6) 
NA ≥64 35.7 2 100 – (n 
= 8) 
NA ≥16 21.4 ≥16 28.6 ≥32 NA 0.12 100 
All 
countries 
123 ≥16 NA ≥32 22.8 ≥128 NA ≥32 
(n = 
15) 
NA ≥64 18.7 2 100 ≥32 
(n = 
108) 
NA ≥16 50.4 ≥16 22.8 ≥32 NA 0.25 100 
Vancomycin-resistant E. faecium 
Israel 27 ≥16 NA ≥32 3.7 ≥128 NA – NA ≥64 3.7 2 100 ≥32 
(n = 
27) 
NA ≥16 55.6 ≥16 7.4 ≥32 NA 0.25 100 
Oman 1 – NA – [0] – NA – NA – [0] – [1] – (n 
= 1) 
NA – [1] – [0] – NA – [1] 
Pakistan 3 – NA – [0] – NA – (n 
= 3) 
NA – [0] – [3] – NA – [2] – [0] – NA – [3] 
Saudi 
Arabia 
1 – NA – [0] – NA – NA – [0] – [1] – (n 
= 1) 
NA – [1] – [0] – NA – [1] 
All 
countries 
32 ≥16 NA ≥32 3.1 ≥128 NA – (n 
= 3) 
NA ≥64 3.1 2 100 ≥32 
(n = 
29) 
NA ≥16 59.4 ≥16 6.3 ≥32 NA 0.25 100 
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Table 1b 
MIC90 (in mg/L) and percent antimicrobial susceptibility (%S) for macrolides and clindamycin against isolates of Streptococcus pneumoniae 
(including penicillin-resistant isolates) collected in the Middle East and Africa between 2004 and 2011 
AZM CLR ERY CLI  N 
MIC90 %S MIC90 %S MIC90 %S MIC90 %S 
S. pneumoniae 
Israel 321 64 76.3 64 76.0 64 76.0 ≥128 87.9
Jordan 14 64 28.6 64 28.6 64 28.6 64 78.6
Mauritius 9 – [4] – [4] – [4] – [4] 
Oman 9 – [7] – [7] – [7] – [8] 
Pakistan 26 64 61.5 ≥128 61.5 ≥128 61.5 ≥128 80.8
Saudi Arabia 15 64 46.7 64 46.7 64 46.7 ≥128 73.3
South Africa 147 ≥128 66.7 ≥128 66.7 ≥128 66.7 ≥128 72.8
All countries 541 64 70.4 64 70.2 64 70.2 ≥128 82.1
Penicillin-non-susceptible S. pneumoniae c 
Israel 154 64 61.0 64 60.4 64 60.4 ≥128 81.2
Jordan 13 64 30.8 64 30.8 64 30.8 64 76.9
Mauritius 7 – [2] – [2] – [2] – [2] 
Oman 4 – [2] – [2] – [2] – [3] 
Pakistan 11 64 36.4 64 36.4 64 36.4 ≥128 72.7
Saudi Arabia 12 64 33.3 64 33.3 64 33.3 ≥128 66.7
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South Africa 105 ≥128 54.3 ≥128 54.3 ≥128 54.3 ≥128 62.9
All countries 306 ≥128 54.6 ≥128 54.2 ≥128 54.2 ≥128 72.5
MIC90, minimum inhibitory concentration required to inhibit 90% of the isolates; AMC, amoxicillin/clavulanic acid; AMP, ampicillin; CRO, 
ceftriaxone; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP, piperacillin/tazobactam; TIG, 
tigecycline; VAN, vancomycin; NA, not applicable. 
a MIC90 and %S are not presented where n < 10; instead, the number of susceptible isolates is given in square brackets. 
b Only countries from which resistant phenotypes have been collected are listed. A single isolate of vancomycin-resistant E. faecalis was 
collected (in Israel) so is not listed here. 
c Penicillin-intermediate + penicillin-resistant. 
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Table 2a 
MIC90 (in mg/L) and percent antimicrobial susceptibility (%S) among Gram-negative isolates (including resistant phenotypes) collected in the 
Middle East and Africa between 2004 and 2011 a,b 
AMK AMC AMP FEP CRO IPM LVX MEM MIN TZP TIG  N 
MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90 %S 
Enterobacter spp. 
Israel 611 2 99.3 ≥64 2.3 ≥64 3.4 8 94.4 64 61.5 – – 2 90.2 0.12 
(n = 
611) 
97.2 16 59.7 64 75.1 2 94.8
Jordan 45 4 97.8 ≥64 0.0 ≥64 2.2 32 80.0 ≥128 62.2 – – 8 82.2 0.25 
(n = 
45) 
100 16 46.7 128 80.0 1 97.8
Lebanon 18 4 100 ≥64 5.6 ≥64 5.6 8 100 ≥128 77.8 1 (n 
= 18) 
94.4 0.06 100 – – 4 100 64 83.3 1 100 
Mauritius 10 16 90.0 ≥64 0.0 ≥64 0.0 ≥64 60.0 ≥128 10.0 – – 1 90.0 0.5 (n 
= 10) 
90.0 ≥32 20.0 ≥256 60.0 1 100 
Namibia 10 1 100 ≥64 10.0 ≥64 0.0 1 100 64 80.0 – – 0.25 100 0.12 
(n = 
10) 
100 8 70.0 32 80.0 1 100 
Page 27 of 45
Ac
ce
pte
d M
an
us
cri
pt
28 
 
Oman 23 2 100 ≥64 4.3 ≥64 0.0 16 87.0 ≥128 78.3 – – 8 87.0 0.12 
(n = 
23) 
95.7 4 91.3 32 87.0 1 100 
Pakistan 45 8 91.1 ≥64 4.4 ≥64 0.0 ≥64 57.8 ≥128 33.3 1 (n 
= 44) 
97.7 ≥16 80.0 – (n 
= 1) 
[1] ≥32 60.0 ≥256 73.3 1 97.8
Saudi 
Arabia 
49 8 98.0 ≥64 4.1 ≥64 0.0 16 87.8 ≥128 69.4 – – 1 93.9 0.25 
(n = 
49) 
100 16 61.2 128 75.5 1 93.9
South 
Africa 
326 8 96.0 ≥64 8.3 ≥64 3.1 8 90.2 ≥128 69.3 1 (n 
= 
100) 
98.0 4 88.3 0.5 (n 
= 
226) 
93.8 ≥32 79.4 64 82.8 2 95.7
All 
countries 
1137 4 97.9 ≥64 4.2 ≥64 2.9 8 90.6 ≥128 63.3 1 (n 
= 
162) 
97.5 4 89.3 0.25 
(n = 
975) 
96.6 16 66.0 64 77.7 2 95.5
Escherichia coli 
Israel 651 8 98.8 32 58.5 ≥64 22.4 16 87.1 ≥128 68.5 – – ≥16 58.5 ≤0.06 
(n = 
651) 
96.5 16 65.1 16 92.0 1 100 
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Jordan 48 8 100 32 45.8 ≥64 4.2 ≥64 52.1 ≥128 37.5 – – ≥16 33.3 0.12 
(n = 
48) 
100 ≥32 54.2 ≥256 79.2 0.5 97.9
Lebanon 27 8 100 16 44.4 ≥64 22.2 32 74.1 ≥128 63.0 0.5 (n 
= 27) 
100 ≥16 55.6 – – 16 70.4 16 96.3 0.25 100 
Mauritius 17 16 100 16 64.7 ≥64 23.5 ≥64 64.7 ≥128 64.7 – – ≥16 58.8 0.25 
(n = 
17) 
100 16 70.6 64 70.6 0.5 100 
Namibia 23 4 100 16 47.8 ≥64 4.3 1 95.7 8 87.0 – – 1 91.3 ≤0.06 
(n = 
23) 
100 ≥32 47.8 64 87.0 0.5 100 
Oman 26 4 100 16 65.4 ≥64 30.8 16 84.6 ≥128 76.9 – – 8 61.5 ≤0.06 
(n = 
26) 
100 16 73.1 8 92.3 0.25 100 
Pakistan 72 8 95.8 ≥64 47.2 ≥64 13.9 ≥64 63.9 ≥128 50.0 0.5 (n 
= 72) 
100 ≥16 37.5 – – 16 66.7 32 87.5 0.5 100 
Saudi 
Arabia 
48 8 95.8 32 64.6 ≥64 29.2 ≥64 68.8 ≥128 66.7 – – ≥16 58.3 ≤0.06 
(n = 
48) 
100 16 64.6 64 83.3 0.25 100 
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South 
Africa 
326 4 99.1 32 63.5 ≥64 23.0 8 93.9 8 86.2 0.5 (n 
= 
122) 
97.5 ≥16 76.1 ≤0.06 
(n = 
204) 
95.6 16 66.9 32 89.9 0.5 100 
All 
countries 
1238 8 98.7 32 58.6 ≥64 21.5 32 85.0 ≥128 71.2 0.5 (n 
= 
221) 
98.6 ≥16 61.6 ≤0.06 
(n = 
1017)
96.9 16 65.3 16 90.1 0.5 99.9
ESBL-positive E. coli 
Israel 113 16 96.5 ≥64 23.9 ≥64 0.0 ≥64 42.5 ≥128 0.9 – – ≥16 15.0 0.25 
(n = 
113) 
92.9 ≥32 56.6 128 79.6 1 100 
Jordan 30 8 100 ≥64 36.7 ≥64 0.0 ≥64 23.3 ≥128 0.0 – – ≥16 30.0 0.12 
(n = 
30) 
100 ≥32 56.7 128 80.0 0.5 96.7
Mauritius 6 – [6] – [1] – [0] – [0] – [0] – – – [0] – (n 
= 6) 
[6] – [4] – [1] – [6] 
Namibia 1 – [1] – [1] – [0] – [1] – [0] – – – [1] – (n 
= 1) 
[1] – [0] – [1] – [1] 
Oman 6 – [6] – [1] – [0] –  [2] – [0] – – – [2] – (n 
= 6) 
[6] – [4] – [6] – [6] 
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Pakistan 22 8 95.5 ≥64 18.2 ≥64 4.5 ≥64 22.7 ≥128 0.0 0.25 
(n = 
22) 
100 ≥16 4.5   ≥32 50.0 16 90.9 0.5 100 
Saudi 
Arabia 
15 8 93.3 32 46.7 ≥64 0.0 ≥64 6.7 ≥128 0.0 – – ≥16 13.3 ≤0.06 
(n = 
15) 
100 ≥32 53.3 128 73.3 0.25 100 
South 
Africa 
12 8 100 32 25.0 ≥64 0.0 ≥64 41.7 ≥128 0.0 – (n 
= 4) 
[4] ≥16 41.7 – (n 
= 8) 
[8] 16 58.3 32 75.0 0.5 100 
All 
countries 
205 8 97.1 ≥64 26.8 ≥64 0.5 ≥64 33.7 ≥128 0.5 0.25 
(n = 
26) 
100 ≥16 18.0 0.12 
(n = 
179) 
95.5 ≥32 56.1 128 79.0 1 99.5
Klebsiella pneumoniae 
Israel 586 32 89.8 ≥64 49.7 ≥64 0.9 ≥64 66.2 ≥128 52.9 – – ≥16 56.3 ≥32 
(n = 
586) 
86.2 ≥32 50.5 ≥256 64.3 2 92.7
Jordan 47 8 95.7 16 57.4 ≥64 2.1 ≥64 68.1 ≥128 55.3 – – 4 80.9 0.25 
(n = 
47) 
100 8 68.1 16 91.5 1 93.6
Mauritius 7 – [6] – [1] – [0] – [1] – [1] – – – [2] – (n 
= 7) 
[6] – [1] – [2] – [6] 
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Namibia 23 2 100 16 60.9 ≥64 0.0 16 87.0 ≥128 69.6 – – 0.5 100 ≤0.06 
(n = 
23) 
100 ≥32 69.6 64 82.6 1 100 
Oman 24 2 100 8 91.7 ≥64 0.0 ≤0.5 100 ≤0.06 95.8 – – 0.06 100 ≤0.06 
(n = 
24) 
100 4 91.7 2 100 0.5 100 
Pakistan 62 ≥128 79.0 ≥64 41.9 ≥64 0.0 ≥64 50.0 ≥128 37.1 0.5 (n 
= 60) 
100 8 82.3 – (n 
= 2) 
[1] 16 62.9 64 82.3 2 93.5
Saudi 
Arabia 
47 16 93.6 32 63.8 ≥64 2.1 ≥64 59.6 ≥128 57.4 – – ≥16 80.9 0.12 
(n = 
47) 
93.6 ≥32 66.0 ≥256 76.6 2 95.7
South 
Africa 
309 16 93.5 ≥64 51.8 ≥64 1.6 ≥64 62.1 ≥128 45.3 1 (n 
= 
114) 
94.7 ≥16 69.6 8 (n 
= 
195) 
88.2 ≥32 63.8 ≥256 75.1 2 93.5
All 
countries 
1105 16 91.0 ≥64 51.7 ≥64 1.1 ≥64 64.8 ≥128 51.2 1 (n 
= 
174) 
96.6 ≥16 65.2 8 (n 
= 
931) 
88.3 ≥32 57.4 ≥256 71.0 2 93.4
ESBL-positive K. pneumoniae 
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Israel 151 16 90.7 ≥64 9.9 ≥64 0.0 ≥64 26.5 ≥128 0.7 – – ≥16 31.1 0.25 
(n = 
151) 
93.4 ≥32 34.4 ≥256 41.7 4 84.8
Jordan 21 8 90.5 32 19.0 ≥64 0.0 ≥64 28.6 ≥128 0.0 – – 4 66.7 0.25 
(n = 
21) 
100 8 61.9 32 85.7 4 85.7
Namibia 3 – [3] – [0] – [0] – [2] – [0] – – – [3] – (n 
= 3) 
[3] – [1] – [1] – [3] 
Oman 1 – [1] – [0] – [0] – [1] – [0] – – – [1] – (n 
= 1) 
[1] – [1] – [1] – [1] 
Pakistan 33 ≥128 63.6 ≥64 15.2 ≥64 0.0 ≥64 24.2 ≥128 0.0 0.5 (n 
= 33) 
100 8 78.8 – – ≥32 48.5 ≥256 72.7 2 93.9
Saudi 
Arabia 
20 16 90.0 32 30.0 ≥64 0.0 ≥64 10.0 ≥128 5.0 – – ≥16 60.0 0.12 
(n = 
20) 
90.0 ≥32 45.0 ≥256 55.0 2 90.0
South 
Africa 
135 16 92.6 ≥64 21.5 ≥64 0.0 ≥64 32.6 ≥128 1.5 1 (n 
= 46) 
95.7 ≥16 46.7 16 (n 
= 89) 
84.3 ≥32 54.1 ≥256 60.0 2 91.9
All 
countries 
364 32 89.0 ≥64 16.2 ≥64 0.0 ≥64 28.3 ≥128 1.1 1 (n 
= 79) 
97.5 ≥16 45.6 0.5 (n 
= 
285) 
90.9 ≥32 45.3 ≥256 54.7 4 88.7
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Klebsiella oxytoca 
Israel 54 4 94.4 ≥64 81.5 ≥64 0.0 16 88.9 64 79.6 – – 8 77.8 2 (n 
= 54) 
88.9 16 85.2 ≥256 83.3 1 98.1
Jordan 1 – [1] – [0] – [0] – [1] – [1] – – – [1] – (n 
= 1) 
[1]  – [1] – [1] – [1] 
Mauritius 4 – [4] – [3] – [1] – [3] – [3] – – – [3] – (n 
= 4) 
[4]  – [3] – [3] – [4] 
Namibia 2 – [2] – [2] – [0] – [2] – [2] – – – [2] – (n 
= 2) 
[2]  – [1] – [2] – [2] 
Oman 2 – [2] – [2] – [0] – [2] – [2] – – – [2] – (n 
= 2) 
[2]  – [2] – [2] – [2] 
Pakistan 13 ≥128 84.6 ≥64 38.5 ≥64 0.0 32 61.5 ≥128 38.5 8 (n 
= 12) 
83.3 8 84.6 – (n 
= 1) 
[1]  16 69.2 64 84.6 1 92.3
Saudi 
Arabia 
1 – [1] – [0] – [0] – [0] – [0] – – – [0] – (n 
= 1) 
[1]  – [0] – [0] – [0] 
South 
Africa 
44 4 100 16 79.5 ≥64 0.0 4 90.9 16 81.8 2 (n 
= 14) 
78.6 0.5 93.2 ≤0.06 
(n = 
30) 
100 16 81.8 16 90.9 1 97.7
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All 
countries 
121 8 95.9 ≥64 75.2 ≥64 0.8 16 86.0 ≥128 76.0 8 (n 
= 26) 
80.8 8 84.3 0.12 
(n = 
95) 
93.7 16 81.0 64 86.0 1 96.7
Serratia marcescens 
Israel 243 4 98.4 ≥64 2.5 ≥64 1.7 2 97.5 8 81.1 – – 1 93.4 0.25 
(n = 
243) 
98.8 16 51.0 8 96.3 2 91.8
Jordan 17 16 94.1 ≥64 5.9 ≥64 0.0 16 88.2 64 76.5 – – 1 100 0.12 
(n = 
17) 
100 16 23.5 8 100 2 94.1
Mauritius 6 – [6] – [0] – [0] – [6] – [5] – – – [6] – (n 
= 6) 
[6]  – [2] – [6] – [6] 
Oman 3 – [3] – [0] – [0] – [3] – [2] – – – [3] – (n 
= 3) 
[3]  – [3] – [3] – [3] 
Pakistan 24 ≥128 83.3 ≥64 4.2 ≥64 0.0 ≥64 83.3 ≥128 50.0 1 (n 
= 23) 
95.7 8 79.2 – (n 
= 1) 
[1]  8 87.5 16 91.7 2 95.8
Saudi 
Arabia 
18 4 100 ≥64 0.0 ≥64 0.0 4 94.4 32 66.7 – – 0.5 100 0.12 
(n = 
18) 
94.4 8 61.1 ≥256 72.2 2 94.4
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South 
Africa 
133 4 99.2 ≥64 8.3 ≥64 5.3 2 96.2 8 78.9 1 (n 
= 41) 
95.1 1 96.2 0.12 
(n = 
92) 
98.9 8 87.2 8 97.7 2 99.2
All 
countries 
444 4 97.7 ≥64 4.3 ≥64 2.5 2 95.9 16 77.9 1 (n 
= 64) 
95.3 1 94.1 0.12 
(n = 
380) 
98.7 8 63.3 8 95.7 2 94.6
Pseudomonas aeruginosa 
Israel 498 16 90.8 ≥64 NA ≥64 NA 16 79.9 ≥128 NA – – ≥16 64.7 16 (n 
= 
498) 
75.9 ≥32 NA 128 67.3 16 NA 
Jordan 39 64 87.2 ≥64 NA ≥64 NA 32 82.1 ≥128 NA – – ≥16 64.1 16 (n 
= 39) 
74.4 ≥32 NA 64 79.5 ≥32 NA 
Lebanon 19 8 100 ≥64 NA ≥64 NA ≥64 68.4 ≥128 NA 8 (n 
= 19) 
78.9 ≥16 68.4 – – ≥32 NA 128 68.4 ≥32 NA 
Mauritius 8 – [4] – NA – NA – [6] – NA – – – [3] – (n 
= 8) 
[4] – NA – [7] – NA 
Namibia 22 16 95.5 ≥64 NA ≥64 NA 16 86.4 ≥128 NA – – 4 81.8 1 (n 
= 22) 
100 ≥32 NA 16 95.5 16 NA 
Oman 20 4 90.0 ≥64 NA ≥64 NA 16 85.0 ≥128 NA – – ≥16 80.0 16 (n 
= 20) 
80.0 ≥32 NA 32 80.0 ≥32 NA 
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Pakistan 60 ≥128 76.7 ≥64 NA ≥64 NA ≥64 66.7 ≥128 NA 8 (n 
= 59) 
74.6 ≥16 60.0 – (n 
= 1) 
[1] ≥32 NA 128 66.7 16 NA 
Saudi 
Arabia 
38 64 84.2 ≥64 NA ≥64 NA ≥64 73.7 ≥128 NA – – ≥16 73.7 8 (n 
= 38) 
81.6 ≥32 NA ≥256 71.1 16 NA 
South 
Africa 
271 32 85.6 ≥64 NA ≥64 NA 32 77.9 ≥128 NA 8 (n 
= 94) 
77.7 ≥16 65.3 ≥32 
(n = 
177) 
71.2 ≥32 NA 128 80.4 ≥32 NA 
All 
countries 
975 32 88.0 ≥64 NA ≥64 NA 32 78.4 ≥128 NA 8 (n 
= 
172) 
76.7 ≥16 65.4 16 (n 
= 
803) 
75.6 ≥32 NA 128 72.6 ≥32 NA 
Acinetobacter baumannii 
Israel 342 ≥128 25.1 ≥64 NA ≥64 NA ≥64 26.6 ≥128 8.5 – – ≥16 21.6 ≥32 
(n = 
342) 
32.2 8 61.7 ≥256 16.7 2 NA 
Jordan 20 ≥128 45.0 ≥64 NA ≥64 NA ≥64 25.0 ≥128 0.0 – – ≥16 40.0 ≥32 
(n = 
20) 
30.0 8 75.0 ≥256 25.0 2 NA 
Mauritius 9 – [6] – NA – NA – [1] – [0] – – – [1] – (n 
= 9) 
[4] – [7] – [1] – NA 
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Namibia 7 – [7] – NA – NA – [7] – [3] – – – [7] – (n 
= 7) 
[7] – [7] – [6] – NA 
Oman 17 8 94.1 ≥64 NA ≥64 NA 32 82.4 ≥128 41.2 – – 4 70.6 2 (n 
= 17) 
100 4 100 128 82.4 0.5 NA 
Pakistan 40 ≥128 20.0 ≥64 NA ≥64 NA ≥64 12.5 ≥128 5.0 ≥32 
(n = 
40) 
20.0 ≥16 17.5 – – 4 92.5 ≥256 12.5 1 NA 
Saudi 
Arabia 
30 ≥128 43.3 ≥64 NA ≥64 NA ≥64 16.7 ≥128 3.3 – – ≥16 30.0 ≥32 
(n = 
30) 
20.0 8 80.0 ≥256 13.3 1 NA 
South 
Africa 
199 ≥128 39.2 ≥64 NA ≥64 NA ≥64 24.6 ≥128 15.1 ≥32 
(n = 
75) 
68.0 ≥16 33.2 ≥32 
(n = 
124) 
25.8 16 54.3 ≥256 28.1 1 NA 
All 
countries 
664 ≥128 33.6 ≥64 NA ≥64 NA ≥64 26.7 ≥128 10.8 ≥32 
(n = 
115) 
51.3 ≥16 27.7 ≥32 
(n = 
549) 
33.2 16 64.2 ≥256 22.3 2 NA 
Non-baumannii Acinetobacter spp. 
Israel 11 64 63.6 ≥64 NA ≥64 NA ≥64 72.7 ≥128 63.6 – – 8 54.5 ≥32 
(n = 
11) 
72.7 8 81.8 ≥256 72.7 2 NA 
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Lebanon 14 ≥128 7.1 ≥64 NA ≥64 NA ≥64 0.0 ≥128 0.0 ≥32 
(n = 
14) 
21.4 ≥16 0.0 – – 8 85.7 ≥256 0.0 1 NA 
Pakistan 1 – [1] – NA – NA – [1] – [1] – (n 
= 1) 
[1] – [1] – – – [1 – [1] – NA 
South 
Africa 
7 – [4] – NA – NA – [5] – [4] – – – [4] – (n 
= 7) 
[4] – [6] – [5] – NA 
All 
countries 
33 ≥128 39.4 ≥64 NA ≥64 NA ≥64 42.4 ≥128 36.4 ≥32 
(n = 
15) 
26.7 ≥16 33.3 ≥32 
(n = 
18) 
66.7 8 84.8 ≥256 42.4 1 NA 
Haemophilus influenzae 
Israel 331 8 NA 2 100 32 78.2 ≤0.5 100 ≤0.06 100 – – 0.03 100 0.25 
(n = 
331) 
100 2 97.6 ≤0.06 100 0.25 100 
Jordan 15 8 NA 2 100 32 80.0 ≤0.5 100 ≤0.06 100 – – 0.06 100 0.25 
(n = 
15) 
100 1 100 ≤0.06 100 0.25 100 
Lebanon 16 4 NA 2 100 ≥64 81.3 ≤0.5 100 ≤0.06 100 1 (n 
= 16) 
100 0.015 100 – – ≤0.5 100 ≤0.06 100 0.5 87.5
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Mauritius 1 – NA – [1] – [0] – [1] – [1] – – – [1] – (n 
= 1) 
[1] – [1] – [1] – [1] 
Oman 14 8 NA 1 100 8 78.6 ≤0.5 100 ≤0.06 100 – – 0.015 100 0.12 
(n = 
14) 
100 ≤0.5 92.9 ≤0.06 100 0.25 100 
Pakistan 29 8 NA 0.5 100 32 89.7 ≤0.5 100 ≤0.06 100 1 (n 
= 29) 
100 0.5 100 – – 2 93.1 ≤0.06 100 0.25 100 
Saudi 
Arabia 
23 4 NA 2 100 32 73.9 ≤0.5 100 ≤0.06 100 – – 0.015 100 ≤0.06 
(n = 
23) 
100 1 100 ≤0.06 100 0.25 100 
South 
Africa 
176 8 NA 1 100 1 90.3 ≤0.5 100 ≤0.06 100 1 (n 
= 46) 
100 0.03 100 0.25 
(n = 
130) 
100 1 98.9 ≤0.06 99.4 0.25 100 
All 
countries 
605 8 NA 1 100 16 82.1 ≤0.5 100 ≤0.06 100 1 (n 
= 91) 
100 0.03 100 0.25 
(n = 
514) 
100 1 97.9 ≤0.06 99.8 0.25 99.7
β-Lactamase-positive H. influenzae 
Israel 69 8 NA 2 100 ≥64 0.0 ≤0.5 100 ≤0.06 100 – – 0.03 100 0.12 
(n = 
69) 
100 2 97.1 ≤0.06 100 0.25 100 
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Jordan 3 – NA – [3] – [0] – [3] – [3] – – – [3] – (n 
= 3) 
[3] – [3] – [3] – [3] 
Lebanon 3 – NA – [3] – [0] – [3] – [3] – (n 
= 3) 
[3] – [3] – – – [3] – [3] – [2] 
Mauritius 1 – NA – [1] – [0] – [1] – [1] – – – [1] – (n 
= 1) 
[1] – [1] – [1] – [1] 
Oman 3 – NA – [3] – [0] – [3] – [3] – – – [3] – (n 
= 3) 
[3] – [3] – [3] – [3] 
Pakistan 3 – NA – [3] – [0] – [3] – [3] – (n 
= 3) 
[3] – [3] – – – [3] – [3] – [3] 
Saudi 
Arabia 
6 – NA – [6] – [0] – [6] – [6] – – – [6] – (n 
= 6) 
[6] – [6] – [6] – [6] 
South 
Africa 
13 8 NA 4 100 ≥64 0.0 ≤0.5 100 ≤0.06 100 – (n 
= 4) 
[4] 0.015 100 – (n 
= 9) 
[9] 1 100 ≤0.06 100 0.25 100 
All 
countries 
101 8 NA 2 100 ≥64 0.0 ≤0.5 100 ≤0.06 100 1 (n 
= 10) 
100 0.03 100 0.12 
(n = 
91) 
100 2 98.0 ≤0.06 100 0.25 99.0
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Table 2b 
MIC90 (in mg/L) and percent antimicrobial susceptibility (%S) for ceftazidime against 
isolates of Pseudomonas aeruginosa and Acinetobacter baumannii collected in the 
Middle East and Africa between 2004 and 2011 
 N MIC90 %S 
P. aeruginosa 
Israel 498 32 71.1
Jordan 39 32 82.1
Lebanon 19 ≥64 73.7
Mauritius 8 – [5] 
Namibia 22 16 81.8
Oman 20 16 80.0
Pakistan 60 ≥64 65.0
Saudi Arabia 38 32 76.3
South Africa 271 16 84.9
All countries 975 32 75.6
A. baumannii 
Israel 342 ≥64 17.5
Jordan 20 ≥64 30.0
Mauritius 9 – [1] 
Namibia 7 – [7] 
Oman 17 ≥64 82.4
Pakistan 40 ≥64 7.5 
Saudi Arabia 30 ≥64 20.0
South Africa 199 ≥64 25.6
All countries 664 ≥64 22.3
MIC90, minimum inhibitory concentration required to inhibit 90% of the isolates; AMK, 
amikacin; AMC, amoxicillin/clavulanic acid; AMP, ampicillin; FEP, cefepime; CRO, 
ceftriaxone; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; 
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TZP, piperacillin/tazobactam; TIG, tigecycline; ESBL, extended-spectrum β-
lactamase; NA, not applicable. 
a MIC90 and %S are not presented where n < 10; instead, the number of susceptible 
isolates is given in square brackets. 
b Only countries from which resistant phenotypes have been collected are listed. 
Only seven ESBL-positive K. oxytoca isolates were collected (one in Saudi Arabia, 
two in Israel and four in South Africa) so are not listed here. 
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Table 3 
Prevalence of total and resistance phenotypes among isolates collected in the 
Middle East and Africa between 2004 and 2011 
Organism Country Total 
N 
% with resistance 
phenotype (n) a 
Gram-positive isolates 
Meticillin-resistant 
Staphylococcus aureus 
Israel 631 30.1 (190) 
 Jordan 29 31.0 (9) 
 Lebanon 25 32.0 (8) 
 Mauritius 24 45.8 (11) 
 Namibia 24 12.5 (3) 
 Oman 29 13.8 (4) 
 Pakistan 62 12.9 (8) 
 Saudi Arabia 42 23.8 (10) 
 South Africa 350 27.1 (95) 
 Middle 
East/Africa 
1216 27.8 (338) 
Penicillin-resistant 
Streptococcus pneumoniae 
Israel 336 19.9 (67) 
 Jordan 14 71.4 (10) 
 Mauritius 9 – (7) 
 Oman 15 20.0 (3) 
 Pakistan 32 0.0 (0) 
 Saudi Arabia 18 33.3 (6) 
 South Africa 174 25.9 (45) 
 Middle 
East/Africa 
598 23.1 (138) 
Penicillin-non-susceptible S. 
pneumoniae 
Israel 336 48.2 (162) 
 Jordan 14 92.9 (13) 
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 Mauritius 9 – (7) 
 Oman 15 46.7 (7) 
 Pakistan 32 37.5 (12) 
 Saudi Arabia 18 77.8 (14) 
 South Africa 174 68.4 (119) 
 Middle 
East/Africa 
598 55.9 (334) 
Vancomycin-resistant 
Enterococcus faecium 
Israel 79 34.2 (27) 
 Jordan 5 – (0) 
 Mauritius 3 – (0) 
 Oman 1 – (1) 
 Pakistan 13 23.1 (3) 
 Saudi Arabia 8 – (1) 
 South Africa 14 0.0 (0) 
 Middle 
East/Africa 
123 26.0 (32) 
Gram-negative isolates 
ESBL-positive Escherichia coli Israel 651 17.4 (113) 
 Jordan 48 62.5 (30) 
 Lebanon 27 0.0 (0) 
 Mauritius 17 35.3 (6) 
 Namibia 23 4.3 (1) 
 Oman 26 23.1 (6) 
 Pakistan 72 30.6 (22) 
 Saudi Arabia 48 31.3 (15) 
 South Africa 326 3.7 (12) 
 Middle 
East/Africa 
1238 16.6 (205) 
ESBL-positive Klebsiella 
pneumoniae 
Israel 586 25.8 (151) 
 Jordan 47 44.7 (21) 
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 Mauritius 7 – (0) 
 Namibia 23 13.0 (3) 
 Oman 24 4.2 (1) 
 Pakistan 62 53.2 (33) 
 Saudi Arabia 47 42.6 (20) 
 South Africa 309 43.7 (135) 
 Middle 
East/Africa 
1105 32.9 (364) 
BL-positive Haemophilus 
influenzae 
Israel 331 20.8 (69) 
 Jordan 15 20.0 (3) 
 Lebanon 16 18.8 (3) 
 Mauritius 1 – (1) 
 Oman 14 21.4 (3) 
 Pakistan 29 10.3 (3) 
 Saudi Arabia 23 26.1 (6) 
 South Africa 176 7.4 (13) 
 Middle 
East/Africa 
605 16.7 (101) 
ESBL, extended-spectrum β-lactamase; BL, β-lactamase. 
a % prevalence is not presented where N < 10. 
A single isolate of vancomycin-resistant Enterococcus faecalis was collected (in 
Israel) so is not listed here. Only seven ESBL-positive Klebsiella oxytoca isolates 
were collected (one in Saudi Arabia, two in Israel and four in South Africa) so are not 
listed here. 
No isolates of penicillin-non-susceptible S. pneumoniae or vancomycin-resistant E. 
faecium were reported in Lebanon or Namibia; no ESBL-positive K. pneumoniae 
were recorded in Lebanon; and no BL-positive H. influenzae were collected from 
Namibia. 
